Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) is expected to be posting its resultson Thursday, October 29th. Analysts expect the company to announce earnings of ($0.0813) per share for the quarter.
Helix Biopharma Stock Performance
Shares of HBPCF opened at $0.77 on Tuesday. Helix Biopharma has a 52-week low of $0.77 and a 52-week high of $1.73. The business’s fifty day moving average is $1.32 and its 200-day moving average is $1.62.
Helix Biopharma Company Profile
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.
Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth.
Read More
- Five stocks we like better than Helix Biopharma
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
